{"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"units":"Participants"}],"groups":[{"description":"Cohort 1: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (i.e., Gray-zone lymphoma or GZL)\n\nParticipants will be treated with pembrolizumab 200 mg (flat dose) intravenous (IV) every 3 weeks provided they have clinical benefit and no unacceptable toxicity; participants who achieve a complete response (CR) will have the option to stop after 1 year of therapy.","id":"BG000","title":"Cohort 1 Gray-Zone Lymphoma (GZL)"},{"description":"Cohort 2: Extra-nodal diffuse large B-cell lymphoma involving one or more of the specified extra-nodal sites (i.e., extra-nodal DLBCL)\n\nParticipants will be treated with pembrolizumab 200 mg (flat dose) intravenous (IV) every 3 weeks provided they have clinical benefit and no unacceptable toxicity; participants who achieve a complete response (CR) will have the option to stop after 1 year of therapy.","id":"BG001","title":"Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"25.26","value":"56.53"},{"groupId":"BG001","spread":"7.25","value":"65.06"},{"groupId":"BG002","spread":"13","value":"62.93"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"10"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"10"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"9"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"12"}],"units":"Participants"}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"units":"Participants"}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"units":"Participants"}],"title":"Negative"}],"description":"Positive means that tumor cells stained positive for PD-L1 and negative means no staining was visible. This is done by histologic review by pathologists.\n\nNot all participant's received tumor cell analyses due to tissue availability.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No tissue available for analyses for one participant in Cohort 1 and 8 participants in Cohort 2.","title":"Baseline Programmed Death-Ligand 1 (PD-L1) Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}],"units":"Participants"}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"}],"units":"Participants"}],"title":"Negative"}],"description":"Positive means that lymphoma cells were present in the bone marrow at baseline and negative means that no lymphoma was seen by histologic confirmation.\n\nNot all participant's received bone marrow biopsies since per protocol they were only done if clinically indicated.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No bone marrow biopsy performed for 5 participants in cohort 2.","title":"Baseline Bone Marrow Involvement","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"}],"units":"Participants"}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"}],"units":"Participants"}],"title":"Negative"}],"description":"Positive means that lymphoma cells were detected in the CSF by flow cytometry. Negative means no lymphoma cells were detected by flow cytometry.\n\nNot all participant's received lumbar punctures with CSF analysis since per protocol they were only done if clinically indicated.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"2 participants did not receive lumbar punctures in Cohort 1 and Cohort 2.","title":"Baseline Cerebral Spinal Fluid (CSF) Involvement","unitOfMeasure":"Participants"}],"populationDescription":"Baseline data collected for one participant in the DLBCL cohort who withdrew consent is reported in the table."}